Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 7Prostatic Neoplasms 3Uveal Melanoma 2Neoplasms 2Stomach Neoplasms 1Oligodendroglioma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Astrocytoma 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79Bevacizumab 75pembrolizumab 74Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × Protein Subunit Vaccines × Clear all
NCT02126579 2024-02-28

MEL60

University of Virginia

Phase 1/2 Completed
50 enrolled 13 charts
Dermatologic

Melanoma, Neoplasms

NCT00874861 2015-12-08

HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas

University of Pittsburgh

Phase EARLY_PHASE1 Completed
10 enrolled
CNS

Astrocytoma, Neoplasms, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡